These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 20110775)

  • 1. Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells.
    Periyasamy-Thandavan S; Jackson WH; Samaddar JS; Erickson B; Barrett JR; Raney L; Gopal E; Ganapathy V; Hill WD; Bhalla KN; Schoenlein PV
    Autophagy; 2010 Jan; 6(1):19-35. PubMed ID: 20110775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress.
    Kawaguchi T; Miyazawa K; Moriya S; Ohtomo T; Che XF; Naito M; Itoh M; Tomoda A
    Int J Oncol; 2011 Mar; 38(3):643-54. PubMed ID: 21174067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells.
    Komatsu S; Miyazawa K; Moriya S; Takase A; Naito M; Inazu M; Kohno N; Itoh M; Tomoda A
    Int J Oncol; 2012 Apr; 40(4):1029-39. PubMed ID: 22200786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pure antiestrogen-induced G1-arrest in myeloma cells results from the reduced kinase activity of cyclin D3/CDK6 complexes whereas apoptosis is mediated by endoplasmic reticulum-dependent caspases.
    Gauduchon J; Seguin A; Marsaud V; Clay D; Renoir JM; Sola B
    Int J Cancer; 2008 May; 122(9):2130-41. PubMed ID: 18183592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.
    Nawrocki ST; Carew JS; Dunner K; Boise LH; Chiao PJ; Huang P; Abbruzzese JL; McConkey DJ
    Cancer Res; 2005 Dec; 65(24):11510-9. PubMed ID: 16357160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRAP1 role in endoplasmic reticulum stress protection favors resistance to anthracyclins in breast carcinoma cells.
    Sisinni L; Maddalena F; Lettini G; Condelli V; Matassa DS; Esposito F; Landriscina M
    Int J Oncol; 2014 Feb; 44(2):573-82. PubMed ID: 24297638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy targeting ectopic ATP synthase and 26S proteasome induces ER stress in breast cancer cells.
    Chang HY; Huang TC; Chen NN; Huang HC; Juan HF
    Cell Death Dis; 2014 Nov; 5(11):e1540. PubMed ID: 25429617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways.
    Fels DR; Ye J; Segan AT; Kridel SJ; Spiotto M; Olson M; Koong AC; Koumenis C
    Cancer Res; 2008 Nov; 68(22):9323-30. PubMed ID: 19010906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response.
    Ishii Y; Papa L; Bahadur U; Yue Z; Aguirre-Ghiso J; Shioda T; Waxman S; Germain D
    Clin Cancer Res; 2011 Apr; 17(8):2292-300. PubMed ID: 21292820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of estrogen receptor-α induces autophagy and inhibits antiestrogen-mediated unfolded protein response activation, promoting ROS-induced breast cancer cell death.
    Cook KL; Clarke PA; Parmar J; Hu R; Schwartz-Roberts JL; Abu-Asab M; Wärri A; Baumann WT; Clarke R
    FASEB J; 2014 Sep; 28(9):3891-905. PubMed ID: 24858277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance.
    Samaddar JS; Gaddy VT; Duplantier J; Thandavan SP; Shah M; Smith MJ; Browning D; Rawson J; Smith SB; Barrett JT; Schoenlein PV
    Mol Cancer Ther; 2008 Sep; 7(9):2977-87. PubMed ID: 18790778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.
    Kao C; Chao A; Tsai CL; Chuang WC; Huang WP; Chen GC; Lin CY; Wang TH; Wang HS; Lai CH
    Cell Death Dis; 2014 Nov; 5(11):e1510. PubMed ID: 25375375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells.
    Komatsu S; Moriya S; Che XF; Yokoyama T; Kohno N; Miyazawa K
    Biochem Biophys Res Commun; 2013 Jul; 437(1):41-7. PubMed ID: 23792097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis.
    Kraus M; Malenke E; Gogel J; Müller H; Rückrich T; Overkleeft H; Ovaa H; Koscielniak E; Hartmann JT; Driessen C
    Mol Cancer Ther; 2008 Jul; 7(7):1940-8. PubMed ID: 18645004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.
    Milani M; Rzymski T; Mellor HR; Pike L; Bottini A; Generali D; Harris AL
    Cancer Res; 2009 May; 69(10):4415-23. PubMed ID: 19417138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autophagy facilitates the progression of ERalpha-positive breast cancer cells to antiestrogen resistance.
    Schoenlein PV; Periyasamy-Thandavan S; Samaddar JS; Jackson WH; Barrett JT
    Autophagy; 2009 Apr; 5(3):400-3. PubMed ID: 19221464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated sestrin-2 regulation.
    Brüning A; Rahmeh M; Friese K
    Mol Oncol; 2013 Dec; 7(6):1012-8. PubMed ID: 23916134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic B-RAF signaling in melanoma impairs the therapeutic advantage of autophagy inhibition.
    Armstrong JL; Corazzari M; Martin S; Pagliarini V; Falasca L; Hill DS; Ellis N; Al Sabah S; Redfern CP; Fimia GM; Piacentini M; Lovat PE
    Clin Cancer Res; 2011 Apr; 17(8):2216-26. PubMed ID: 21270111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
    Roué G; Pérez-Galán P; Mozos A; López-Guerra M; Xargay-Torrent S; Rosich L; Saborit-Villarroya I; Normant E; Campo E; Colomer D
    Blood; 2011 Jan; 117(4):1270-9. PubMed ID: 21106982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.